Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 28, 2026Investment Snapshot
- Trading 99% below Graham Number ($45.83) — significant margin of safety
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -39.3%
Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $1 million . Key value metrics: P/E ratio 0.1, P/B ratio 0.04, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Galmed Pharmaceuticals Ltd. - Ordinary Shares — Fundamental Analysis Summary
Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD) is trading 99% below its Graham Number of $45.83 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 0.1x.
On financial health, GLMD shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -39.3% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for GLMD is 55/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
GLMD shows earnings declining at 9%.